Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01220726 · ClinicalTrials.gov registry record · Phase 3
Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction
A Phase 3 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT01220726: Completed Phase 3 study, sponsored by Weill Medical College of Cornell University.
NCT01220726 is a Phase 3 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 30 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01220726, a Phase 3 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a prospective, randomized, double-blind study comparing intravesical injection of BOTOX to placebo. Study subjects will be randomized (1:1 ratio) to one of the following treatment groups:
Primary Outcome
This is the measure of urinary frequency at baseline for those in the placebo and botox arms to day 270
Interventions
- DRUG Placebo
- DRUG Botox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-11-13 |
| Phase | Phase 3 |
What the finished NCT01220726 record still lists
NCT01220726 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01220726 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01220726 about?
NCT01220726 is a clinical study titled "Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction". This is a prospective, randomized, double-blind study comparing intravesical injection of BOTOX to placebo. Study subjects will be randomized (1:1 ratio) to one of the following treatment groups:
What is the current status of trial NCT01220726?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2009-06. Estimated completion is 2012-11-13.
What interventions are being tested in trial NCT01220726?
The interventions under investigation include: Placebo (DRUG), Botox (DRUG).
Who is sponsoring clinical trial NCT01220726?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01220726's enrollment target sits among peer trials
30 1917th of 2000 higher than 68 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia